Altered glutamate signaling in Parkinson’s disease patients with REM sleep behavior disorder

Christopher E. J. Doppler, Aline Seger, Ezequiel Farrher, Cláudia Régio Brambilla, Lukas Hensel, Christian Filß, Ana Gogishvili, N. Jon Shah, Christoph Lerche, Bernd Neumaier, Karl‐Josef Langen, Gereon R. Fink, Michael SommerauermedRxiv 2023 · DOI

Introduction

Parkinson’s disease (PD) is characterized by significant clinical heterogeneity. While many patients experience a slow progression of motor symptoms, a specific subgroup—those with Rapid Eye Movement (REM) sleep behavior disorder (RBD)—exhibit a more "malignant" phenotype. This phenotype is defined by faster motor decline, increased non-motor symptom burden, and a generally poorer prognosis.

While dopamine depletion is the primary hallmark of PD, it does not fully account for the severity of the PD+RBD subtype. Recent research has turned toward the glutamatergic system, the brain's primary excitatory signaling pathway, to understand this divergence. This study investigates whether a disbalance in glutamate signaling—specifically the relationship between glutamate metabolites and their receptors—underlies the clinical severity of PD with RBD.

Methodology

To investigate these mechanisms, researchers employed a hybrid PET/MR system, allowing for the simultaneous measurement of two distinct aspects of the glutamatergic system in 48 participants (16 PD+RBD, 17 PD-RBD, and 15 healthy controls).

  1. Receptor Availability (PET): Using the radiotracer $^{11}$C-ABP688, which binds to metabotropic glutamate receptor 5 (mGluR5), the team measured the total volume of distribution ($V_T$) across 13 brain regions. This indicates the density or sensitivity of the "receivers" for glutamate signals.
  2. Metabolite Concentration (MR Spectroscopy): Using single-voxel STEAM spectroscopy in the left putamen, researchers measured the actual levels of glutamate, glutamine, and glutathione (the "signal" itself).
  3. Sleep Assessment: Overnight video-polysomnography (vPSG) was used to confirm RBD status by measuring REM sleep without atonia (RSWA), the loss of normal muscle paralysis during REM sleep.

Key Findings

The Receptor-Metabolite Mismatch

The study revealed a striking discrepancy: patients with PD+RBD showed globally elevated mGluR5 receptor availability ($V_T$) compared to both PD-RBD patients and healthy controls ($F(2,45) = 5.579, p = 0.007$). This elevation was observed across all cortical and subcortical regions examined.

Crucially, despite this receptor "overdrive," the actual concentrations of glutamate and its metabolites in the putamen remained normal and did not differ between groups. This suggests that the pathology in PD+RBD is not characterized by an excess of glutamate, but rather by an increased sensitivity or upregulation of the receptors that respond to it.

Clinical and Physiological Correlations

The elevation in mGluR5 availability was not merely a biological marker but correlated directly with clinical severity:

  • Dopaminergic Response: Higher mGluR5 levels in motor regions (such as the putamen and motor cortex) were significantly associated with a poorer response to dopaminergic medication ($F(1,30) = 5.823, p = 0.022$). This suggests that overactive glutamate signaling may interfere with the efficacy of standard Levodopa treatments.
  • Sleep Pathology: The degree of REM sleep without atonia—the hallmark of RBD—correlated linearly with mGluR5 availability ($F(1,42) = 5.600, p = 0.023$), linking the sleep disorder directly to the altered glutamatergic state.

Discussion and Implications

The findings suggest that the "malignant" progression of PD+RBD may be driven by chronic excitotoxicity. Because mGluR5 receptors modulate NMDA receptor activity, their upregulation could lead to the over-stimulation and eventual death of neurons, explaining the faster motor decline in these patients.

Furthermore, the negative correlation with dopaminergic response provides a potential explanation for why some PD patients respond less effectively to traditional therapies. In the basal ganglia, glutamate and dopamine often act in opposition; an upregulated glutamatergic "brake" may simply be too strong for dopaminergic "gas" to overcome.

Future Directions

While the study was limited by single-voxel spectroscopy and the lack of a perfect PET reference region, the results provide a compelling rationale for a precision medicine approach in Parkinson’s. Specifically, mGluR5 antagonists—drugs designed to block these receptors—may hold significant therapeutic potential for the PD+RBD subgroup, even if they have shown mixed results in the general PD population. Targeting this specific glutamatergic disbalance could be the key to slowing progression in the most vulnerable Parkinson’s patients.

Summary updated

Abstract

Abstract Background and Objectives Clinical heterogeneity of patients with Parkinson’s disease is well recognized. Parkinson’s disease with rapid eye movement (REM) sleep behavior disorder (RBD) is a more malignant phenotype with faster motor progression and higher non-motor symptom burden. However, the neural mechanisms underlying this clinical divergence concerning disbalances in neurotransmitter systems remain elusive. Methods Combining magnetic resonance (MR) spectroscopy and 11 C-ABP688 positron emission tomography (PET) on PET/MR hybrid system, we simultaneously investigated two different mechanisms of glutamate signaling in patients with Parkinson’s disease. Thirty-three patients were grouped according to their RBD status in overnight video-polysomnography and compared to 15 age- and sex-matched healthy control (HC) subjects. Total volumes of distribution (V T ) of 11 C-ABP688 were estimated with metabolite-corrected plasma concentrations during steady-state conditions between minutes 45 to 60 of the scan following a bolus-infusion protocol. Glutamate, glutamine, and glutathione levels were investigated with single voxel STEAM MR spectroscopy of the left putamen. Results We measured globally elevated V T of 11 C-ABP688 in patients with Parkinson’s disease and RBD compared to patients without RBD and HC subjects ( F (2,45) = 5.579, p = 0.007). Conversely, glutamatergic metabolites did not differ between groups and did not correlate with the regional V T of 11 C-ABP688. V T of 11 C-ABP688 correlated with the amount of REM sleep without atonia ( F (1,42) = 5.600, p = 0.023), and with dopaminergic treatment response in Parkinson’s disease patients ( F (1,30) = 5.823, p = 0.022). Conclusion Our results suggest that patients with Parkinson’s disease and RBD exhibit altered glutamatergic signaling indicated by higher V T of 11 C-ABP688 despite unaffected glutamate metabolism. The disbalance of glutamate receptors and neurotransmitter might indicate a novel mechanism contributing to the heterogeneity of Parkinson’s disease and warrants further investigation of drugs targeting mGluR5.
BibTeX
@misc{doppler2023altered,
  author = {Christopher E. J. Doppler and Aline Seger and Ezequiel Farrher and Cláudia Régio Brambilla and Lukas Hensel and Christian Filß and Ana Gogishvili and N. Jon Shah and Christoph Lerche and Bernd Neumaier and Karl‐Josef Langen and Gereon R. Fink and Michael Sommerauer},
  title = {{Altered glutamate signaling in Parkinson’s disease patients with REM sleep behavior disorder}},
  year = {2023},
  doi = {10.1101/2023.02.14.23285815},
  howpublished = {medRxiv},
}

Loading related content...

Figure